API | pracinostat

pracinostat Report issue

Small molecule Experimental

AACT DrugBank MeSH PubChem

Active Ingredient History

NOW

Pracinostat (SB939) is an orally bioavailable, small-molecule histone deacetylase (HDAC) inhibitor based on hydroxamic acid with potential anti-tumor activity characterized by favorable physicochemical, pharmaceutical, and pharmacokinetic properties. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
- Histone deacetylase 2 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

3-(2-butyl-1-(2-diethylaminoethyl)-1h-benzoimidazol-5-yl)-n-hydroxyacrylamide-hydrochloride | pracinostat | sb939 | sb939 compound

Organizations (17)

Research & Development (17)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (11)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (11)

Healthy Volunteers (Phase 1)

Hematologic Neoplasms (Phase 1)

Leukemia (Phase 1)

Leukemia, Myeloid, Acute (Phase 3)

Myelodysplastic Syndromes (Phase 2)

Myeloproliferative Disorders (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 1)

Non-Smokers (Phase 1)

Prostatic Neoplasms (Phase 2)

Tobacco (Early Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 16
# of Trial Organizations: 17

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue